{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:30:22Z","timestamp":1784320222354,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.diagmicrobio.2019.05.011","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T04:26:20Z","timestamp":1559017580000},"page":"185-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world use of telavancin in the treatment of osteomyelitis"],"prefix":"10.1016","volume":"95","author":[{"given":"Louis D.","family":"Saravolatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry O.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Rikabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Spak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Szpunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0005","series-title":"Vibativ [package insert], San Francisco, CA","author":"Anon","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5114\/ada.2017.72460","article-title":"Increasing rates of daptomycin nnonsuceptible strains WBaranska-Rybak W. Increasing rate of daptomycin non-susceptible strains of Staphylococcus aureus in patients with atopic dermatitis","volume":"6","author":"Blazewicz","year":"2017","journal-title":"Adv Dermatol Allergol"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/dki198","article-title":"Telavancin: In vitro activity against staphylococci in a biofilm model","volume":"56","author":"Gander","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3550-6","article-title":"Factors predictive of relapse in adult bacterial osteomyelitis of long bones","volume":"18","author":"Garcia Del Pozo","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.diagmicrobio.2017.09.004","article-title":"Telavancin for the treatment of methicillin\u2013resistant Staphylococcus aureus bone and joint infections","volume":"89","author":"Harting","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0030","first-page":"27","article-title":"Telavancin, a multifunctional lipogycopeptide disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl2","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0035","first-page":"S61","article-title":"Telavancin: Mechanisms of Action, In Vitro Activity and Mechanisms of Resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0040","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/cid\/cix640","article-title":"Trends in methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010\u20132014","volume":"65","author":"Klein","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10 A","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0045","doi-asserted-by":"crossref","first-page":"S 13","DOI":"10.1016\/j.amjmed.2007.07.010","article-title":"Clinical experience of daptomycin for the treatment of patients with osteomyelitis","volume":"120","author":"Lamp","year":"2007","journal-title":"Am J Med"},{"issue":"9431","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the IDSA for the treatment of MRSA infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0065","first-page":"269","article-title":"Vancomycin resistance and Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0070","first-page":"117","article-title":"Clinical outcomes of osteomyelitis patients infected with methicillin-resistant Staphylococcus aureus","volume":"41","author":"Peyrani","year":"2012","journal-title":"Am J Orthop"},{"issue":"10a","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0075","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjmed.2007.07.008","article-title":"Cubicin Outcomes Registry and Experience (CORE) Methodology","volume":"120","author":"Rolston","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2017.01.034","article-title":"Outpatient treatment of osteomyelitis with Telavancin","volume":"50","author":"Schroeder","year":"2018","journal-title":"Intern J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0090","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0095","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0100","unstructured":"Xu J.X., Schroeder C.P., and Van Anglen L.J.: Outpatient treatment of osteomyelitis with telavancin: A retrospective chart review. In (eds): Poster presented at: American Society of Health-System Pharmacists (ASHP); December 6\u201310, 2015; New Orleans, LA."},{"key":"10.1016\/j.diagmicrobio.2019.05.011_bb0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jac\/dkn490","article-title":"Efficacy of telavancin in the treatment of methicillin\u2013resistant Staphylococcus aureus osteomyelitis; studies with a rabbit model","volume":"63","author":"Yin","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2019.05.011_bb0110","article-title":"Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"10","author":"Zhang","year":"2015","journal-title":"PLOS 1"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318307016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318307016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:17Z","timestamp":1760003537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318307016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0732889318307016"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.011","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of telavancin in the treatment of osteomyelitis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}